TABLE 3.
Haplotype analysis of the CLEC16A variants in PD patients and controls.
| Haplotype a | Control, n (%) | PD, n (%) | P | OR (95% CI) |
|---|---|---|---|---|
| GAGAG | 453.5 (44.99) | 399.7 (38.81) | — | 1.00 |
| AGCGA | 182.8 (18.13) | 197.0 (19.13) | 0.12 | 1.22 (0.95–1.56) |
| AAGAG | 93.3 (9.26) | 120.9 (11.74) | 0.02 b | 1.47 (1.06–2.04) |
| AACGG | 82.2 (8.15) | 98.3 (9.54) | 0.03 b | 1.47 (1.04–2.07) |
| GACAG | 72.2 (7.16) | 75.8 (7.38) | 0.34 | 1.20 (0.82–1.74) |
| Total | 1008.0 (100) | 1030.0 (100) | 0.034 b | — |
a
Haplotype alleles were in the order of rs6498169, rs12708716, rs12917716, rs7200786, and rs2903692. Haplotypes with frequency <3% in both PD patients and controls were excluded from the analysis.
b
P < 0.05. CI, confidence interval; OR, odds ratio; PD, Parkinson’s disease.